Orforglipron activates a peptide-hormone receptor. It is not a peptide.
FOUNDAYO is an FDA-approved oral GLP-1 medicine whose active ingredient is a synthetic small molecule. This guide resolves the naming confusion, then compares the exact product with peptide-based semaglutide, tirzepatide, and investigational retatrutide without turning separate trials into a winner.
GLP-1 is a peptide. Orforglipron is not.
A drug can activate the GLP-1 receptor without copying the peptide structure of the natural hormone. Orforglipron is a non-peptide small molecule designed to activate that receptor. Semaglutide, tirzepatide, and retatrutide are peptide-based molecules.
This distinction affects molecular identity and formulation. It does not by itself prove greater efficacy, fewer side effects, or a better choice for an individual.
Open the exact FOUNDAYO FDA-label record →Receptor, molecule, and product are three separate fields.
Most confusion starts when one field is allowed to answer all three questions.
GLP-1 receptor
The receptor takes its name from glucagon-like peptide-1, a peptide hormone. A receptor name does not dictate that every molecule binding to it must also be a peptide.
Target identity describes what the drug engages. It does not fully describe what the drug is.
Small molecule
The FDA label describes orforglipron as a non-peptide GLP-1 receptor agonist. Semaglutide, tirzepatide, and retatrutide belong to peptide-based molecular programs.
Shared pharmacology does not create shared molecular identity, formulation, evidence, or product equivalence.
FOUNDAYO
FOUNDAYO is the exact US prescription product approved under NDA 220934. The record includes the tablets, company, label, indication, warnings, and manufacturing review.
An ingredient name on an online product does not transfer this approval or authenticate its contents.
ATTAIN-1
The 72-week randomized trial reported group averages under a defined estimand. It did not compare participants directly with retatrutide, injected Wegovy, or Zepbound.
Separate percentages remain separate evidence, even when the products address the same broad condition.
One receptor family. Different kinds of drugs.
Status belongs to the exact product and country. Molecule class alone never establishes approval or superiority.
| Product or program | Molecule | Target | Form and current status |
|---|---|---|---|
| FOUNDAYOOrforglipron | Non-peptide small molecule | GLP-1 receptor agonist | Oral tablet. FDA approved in the United States. |
| WEGOVYSemaglutide | Peptide | GLP-1 receptor agonist | Injection and oral tablet presentations. FDA-approved product record. |
| ZEPBOUNDTirzepatide | Peptide | GIP and GLP-1 receptor agonist | Subcutaneous injection. FDA-approved product record. |
| RetatrutideLY3437943 | Synthetic peptide | GIP, GLP-1, and glucagon receptor agonist | Subcutaneous injection under study. Investigational and not FDA approved. |
Foundayo, orforglipron, price, status, and comparisons.
Every answer is tied to the July 20, 2026 evidence check. Use the current prescribing information for complete medicine-specific safety information.
Is orforglipron a peptide?
No. Orforglipron is a synthetic small molecule. It activates the GLP-1 receptor, which is named for the peptide hormone glucagon-like peptide-1, but receptor target and molecular class are different facts. Semaglutide, tirzepatide, and retatrutide are peptide-based molecules. Orforglipron is not.
What is the brand name for orforglipron?
The FDA-approved US brand is FOUNDAYO. FDA approved the tablets under NDA 220934 on April 1, 2026. The generic ingredient name is orforglipron, and the development code LY3502970 appears in older clinical records.
Is Foundayo FDA approved?
Yes, for a defined adult weight-management population in the United States. Approval belongs to the exact product, presentation, label, and application. It does not authenticate an online research product and it does not create authorization in every other country.
How much weight loss did orforglipron show?
ATTAIN-1 reported an 11.2% mean reduction at 72 weeks for the highest studied group under the treatment-regimen estimand, compared with 2.1% for placebo. That is a randomized trial average, not a prediction for an individual and not a head-to-head result against semaglutide, tirzepatide, or retatrutide.
Is Foundayo better than Wegovy or Zepbound?
No universal winner is established. The approved products differ in molecule class, route, labeled uses, evidence base, contraindications, adverse reactions, access, and cost. Separate trial percentages do not create a head-to-head comparison, and convenience alone does not determine the best option for an individual.
Is orforglipron better than retatrutide?
They answer different questions today. FOUNDAYO is an FDA-approved oral non-peptide GLP-1 medicine. Retatrutide is an investigational injected peptide triple agonist with larger separate-trial weight-loss headlines. No trial has randomized participants between the two, so efficacy, safety, adherence, and preference cannot be ranked fairly from unrelated percentages.
How much does Foundayo cost?
There is no one price for every patient. Insurance, strength, pharmacy, eligibility, and changing manufacturer programs affect the amount paid. FDA approval documents do not establish a retail price. Use Lilly's current coverage and savings page for the offer terms, then verify the actual pharmacy and insurance result.
Is Foundayo available outside the United States?
US approval does not establish availability elsewhere. Lilly reported submissions for weight management and/or type 2 diabetes in more than 40 countries, but each submission still requires a local regulatory decision, indication, label, launch, prescription route, and supply check. Search the destination regulator before treating a country claim as current access.
What are the main Foundayo side-effect boundaries?
The current label carries a boxed warning and describes gastrointestinal and other adverse reactions, contraindications, precautions, interactions, and use in specific populations. A short web answer cannot replace the full prescribing information. The direct DailyMed label below is the current primary reference for complete safety information.
A powder, capsule, research listing, imported presentation, or marketplace product does not inherit NDA 220934. Verify the exact product, prescription route, pharmacy, and local authorization before interpreting an availability claim.
Open the safety and verification center →